Bayer Schering Pharma, Prometheus Reach Agreement on Oncology Mutational Analyses | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories and Bayer Schering Pharma today said they have executed an oncology-focused mutational analyses services agreement, building on a deal reached between the two parties earlier this year.

Information gleaned from the new agreement may lead to better patient stratification in clinical studies and hasten the development of new cancer diagnostics and treatments, Prometheus said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.